Skip to content
10-K

Annual Report

AYTU BIOPHARMA, INC AYTU

0001437749-25-029723

← back to feed
Filed
Sep 23, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Sep 15, 2025 9.91M sh
Capex FY 2025 · Jun 30, 2025 $228K
Capex FY 2025 · Jun 30, 2024 $329K
Operating Cash Flow FY 2025 · Jun 30, 2025 −$1.94M
Operating Cash Flow FY 2025 · Jun 30, 2024 −$1.39M
Long Term Debt FY 2025 · Jun 30, 2025 $10.9M
Cash And Equivalents FY 2025 · Jun 30, 2025 $30.95M
Cash And Equivalents FY 2025 · Jun 30, 2024 $20.01M
Stockholders Equity FY 2025 · Jun 30, 2025 $18.97M
Stockholders Equity FY 2025 · Jun 30, 2024 $27.72M
Stockholders Equity FY 2025 · Jun 30, 2023 $39.36M
Current Liabilities FY 2025 · Jun 30, 2025 $63.06M
Current Liabilities FY 2025 · Jun 30, 2024 $62.23M
Current Assets FY 2025 · Jun 30, 2025 $79.18M
Current Assets FY 2025 · Jun 30, 2024 $61.89M
Total Assets FY 2025 · Jun 30, 2025 $124.18M
Total Assets FY 2025 · Jun 30, 2024 $118.1M
Eps Basic FY 2025 · Jun 30, 2025 −$2.16
Eps Basic FY 2025 · Jun 30, 2024 −$2.86
Rd Expense FY 2025 · Jun 30, 2025 $1.33M
Rd Expense restated FY 2025 · Jun 30, 2024 $2.77M
Net Income FY 2025 · Jun 30, 2025 −$13.56M
Net Income FY 2025 · Jun 30, 2024 −$15.84M
Operating Income FY 2025 · Jun 30, 2025 −$7.83M
Operating Income restated FY 2025 · Jun 30, 2024 −$1.59M
Gross Profit FY 2025 · Jun 30, 2025 $45.83M
Gross Profit restated FY 2025 · Jun 30, 2024 $49.05M
Revenue FY 2025 · Jun 30, 2025 $66.38M
Revenue restated FY 2025 · Jun 30, 2024 $65.18M